HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms

Journal of Acquired Immune Deficiency Syndromes

Volumn 33, Issue 1, 2003, Pages 8-14

  Ravela, Jaideep ^a   Betts, Bradley J ^a   Brun Vézinet, Francoise ^b   Vandamme, Anne Mieke ^c   Descamps, Diane ^b   Van Laethem, Kristel ^c   Smith, Kate ^d   Schapiro, Jonathan M ^a   Winslow, Dean L ^d   Reid, Caroline ^d   Shafer, Robert W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BICHAT HOSPITAL   (France)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d Visible Genetics Inc   (Canada)

Author keywords

Drug resistance; Genotype; HIV 1; Mutation; Protease; Reverse transcriptase

Indexed keywords

ABACAVIR; AMPRENAVIR; DIDANOSINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; PROTEINASE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ALGORITHM; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DRUG SENSITIVITY; GENE ISOLATION; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS GENE;

EID: 0037847549     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200305010-00002     Document Type: Article

References (12)

1. Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA. 2000;283: 2417-2426.
2. EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS. 2001;15:309-320.
3. Shafer RW, Hertogs K, Zolopa AR, et al. High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J Clin Microbiol. 2001;39:1522-1529.
4. Gonzales MJ, Machekano RN, Shafer RW. Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population. J Infect Dis. 2001; 184:998-1006.
5. Meynard JL, Vray M, Morand-Joubert L, et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS. 2002;16:727-736.
6. Shafer RW, Stevenson D, Chan B. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 1999;27:348-352.
7. Van Laethem K, De Luca A, Antinori A, et al. A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Antiviral Ther. 2002; 7:123-129.
8. Reid C, Bassett R, Day S, et al. A dynamic rules-based interpretation system derived by an expert panel is predictive of virological failure. Antiviral Ther. 2002;7:S91.
9. Vandamme AM, Houyez F, Banhegyi D, et al. Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up. Antiviral Ther. 2001;6:21-39.
10. Schmidt B, Walter H, Schwingel E, et al. Comparison of different interpretation systems for genotypic HIV-1 drug resistance data. Antiviral Ther. 2001;6:102.
11. Kijak GH, Rubio AE, Pampuro SE, et al. Discrepant results in the interpretation of HIV-1 drug-resistance genotypic data among widely used algorithms. HIV Med. 2003;4:72-78.
12. Parkin N, Chappey C, Maroldo L, et al. Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information. J Acquir Immune Defic Syndr 2002;31:128-136.